Navigation Links
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
Date:11/23/2009

SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology executive management. He was the former Chief Executive Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen, Denmark.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091123/SF15228)

Dr. Steven Reed, IDC's founder and Chief Executive Officer commented, "I am delighted to welcome Dr. Bruce Carter as a new member of IDC's management team and Board of Directors. His appointment and his broad biotech experience signifies our commitment to building a strong company that delivers on its scientific objectives. He is a great addition to IDC."

"With Dr. Steven Reed's expertise on vaccine adjuvants and Dr. David Baltimore's and Dr. Thomas Dubensky's expertise on the lentivirus-based vectors to introduce antigens to dendritic cells, IDC is poised to develop new improved vaccines to a world that desperately needs them," said Dr. Carter.

Dr. Carter possesses a unique combination of strong leadership skills and technical expertise in progressing healthcare products from the bench to the clinic, and ultimately to the people who need them.

Dr. Carter currently serves on the Board of ZymoGenetics, Dr. Reddy's Laboratories, the Hyderabad, India based generic drug maker, QLT, Inc. Vancouver, Canada and the nonprofit Global Alliance TB Drug Development Board, New York, NY. He joins IDC after a long career in the biotechnology and pharmaceutical arena.

Dr. Carter began his career in drug discovery at G. D. Searle. In 1986, he was appointed as V.P. and Head of Research & Development at ZymoGenetics. In 1994 he became a Corporate Executive V.P. at Novo Nordisk, as well as Chief Scientific Officer. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk and he became the CEO transforming the company from the research arm of a European company to a company that developed and commercialized Recothrom®.

IDC - Innovative Science

IDC's goal is to develop and commercialize new safe and effective vaccine products to prevent or target infectious and malignant diseases. IDC utilizes proprietary Toll-like receptor-4 agonist adjuvant and lentivirus-based vector platforms, which both target dendritic cells and are used to deliver antigens together with desired immunostimulatory signals.

For more information, go to www.immunedesign.com.


Contact:

Cassie Ostrander 206-826-7901 or
cassie.ostrander@immunedesign.com

SOURCE Immune Design Corp.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
2. RNL BIO Rescues a College Student from Autoimmune Hearing Loss
3. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
4. Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
5. Octapharma Aims to Expand U.S. Immune Globulin Therapy Portfolio
6. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
7. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
8. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
9. Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS**
10. AutoImmune Inc. Reports 2009 Second Quarter Financial Results
11. Transposagen Creates a Rat Model of the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... ... 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses ... EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
(Date:10/6/2017)... Boston, Mass. (PRWEB) , ... October 06, 2017 ... ... spotlight female entrepreneurship within the healthcare and technology sector at their fourth annual ... six panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading provider of ... world, is giving back to cancer research with a month-long promotion supporting the advancement ... October 31, shoppers can use promo code PinkRibbon to get 10 percent off their ...
Breaking Biology Technology:
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
Breaking Biology News(10 mins):